GlassScriptPhysician profile
Jennifer Mcgee
NPI 1386353522
$3,196.12
in general payments reported to CMS, 2019-2025
25 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $91.31 · 2023: $503 · 2024: $1,126 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $543.03 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $522.50 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $519.39 | 2023-2025 | |
| Pfizer INC. | $428.83 | 2023-2025 | |
| Axsome Therapeutics, INC. | $184.79 | 2023-2025 | Auvelity, Sunosi |
| Exact Sciences Corporation | $162.95 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.38 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $146.43 | 2022-2025 | Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $103.48 | 2024 | |
| Lilly USA, LLC | $71.82 | 2023-2024 | Mounjaro, Zepbound |
| Aimmune Therapeutics, INC. | $50.00 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.12 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $39.46 | 2024-2025 | Rexulti |
| Amgen INC. | $32.65 | 2023-2024 | Repatha, Otezla |
| Ironshore Pharmaceuticals INC. | $23.79 | 2023 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $21.16 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $19.51 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.08 | 2023 | Eliquis |
| Pulmonx Corporation | $18.31 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.09 | 2023 | Xifaxan |
| Medtronic, INC. | $16.20 | 2025 | Sonicision |
| Kowa Pharmaceuticals America, INC. | $15.46 | 2025 | Zoryve |
| Lundbeck LLC | $14.55 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $14.26 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $13.88 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.